Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchWithdrawnNCT04630210
What this trial is testing

Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity

Who this might be right for
Breast Cancer
Universitaire Ziekenhuizen KU Leuven
Not applicableStudy completedNCT03285568
What this trial is testing

Patterns of Prescribing and Monitoring of Palbociclib

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerEstrogen Receptor-positive Breast Cancer+1 more
Rush University Medical Center 67
Testing effectiveness (Phase 2)Active Not RecruitingNCT01872260
What this trial is testing

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 259
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07173556
What this trial is testing

A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd. 96
Testing effectiveness (Phase 2)Study completedNCT05896566
What this trial is testing

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 231
Large-scale testing (Phase 3)Study completedNCT01564056
What this trial is testing

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Who this might be right for
Breast Cancer
UNICANCER 1,989
Testing effectiveness (Phase 2)Study completedNCT02668666
What this trial is testing

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Who this might be right for
Hormone Receptor Positive Malignant Neoplasm of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastEstrogen Receptor Positive Breast Cancer+2 more
Oana Danciu, MD 49
Testing effectiveness (Phase 2)Study completedNCT00828854
What this trial is testing

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Who this might be right for
ER+ Breast Cancer
Syndax Pharmaceuticals 27
Early research (Phase 1)Study completedNCT02599714
What this trial is testing

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

Who this might be right for
Advanced and Metastatic Breast Cancer
AstraZeneca 54
Testing effectiveness (Phase 2)Looking for participantsNCT07287098
What this trial is testing

Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 600
Large-scale testing (Phase 3)Study completedNCT00949598
What this trial is testing

Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer

Who this might be right for
Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle 177
Early research (Phase 1)Study completedNCT02900664
What this trial is testing

PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Who this might be right for
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Novartis Pharmaceuticals 283
Testing effectiveness (Phase 2)Ended earlyNCT04577963
What this trial is testing

Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Who this might be right for
Triple Negative Breast CancerEndometrial CancerSolid Tumor, Unspecified, Adult+1 more
Hutchmed 52
Testing effectiveness (Phase 2)Ended earlyNCT02374099
What this trial is testing

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Who this might be right for
Breast Neoplasms
Celgene 97
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Large-scale testing (Phase 3)Looking for participantsNCT05512364
What this trial is testing

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Who this might be right for
ER-positive Breast CancerHER2-negative Breast CancerStage IIB Breast Cancer+1 more
European Organisation for Research and Treatment of Cancer - EORTC 220
Testing effectiveness (Phase 2)Study completedNCT00454805
What this trial is testing

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Who this might be right for
Advanced Breast Cancer
AstraZeneca 75
Large-scale testing (Phase 3)Looking for participantsNCT05774951
What this trial is testing

Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Who this might be right for
Breast Cancer, Early Breast Cancer
AstraZeneca 4,300
Large-scale testing (Phase 3)Looking for participantsNCT06341621
What this trial is testing

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

Who this might be right for
Breast Cancer
Fudan University 1,900
Testing effectiveness (Phase 2)Study completedNCT00540358
What this trial is testing

Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 123
Next Page